Showing results (451-460 of 645) with videos related to
Sort By:
Pageof 65
Journal of the Neurological Sciences|July 19, 2017
Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment centerShnehal Patel, Xiomara Garcia, Mohammad Edrees Mohammad, et al.Annales Francaises D'Anesthesie Et De Reanimation|December 8, 2004
[Recombinant activated factor VII as a life-saving therapy for severe postpartum haemorrhage unresponsive to conservative traditional management]A Brice, U Hilbert, S Roger-Christoph, et al.Journal De Gynecologie, Obstetrique Et Biologie De La Reproduction|October 25, 2011
[Risk factors for recurrence of ectopic pregnancy]M De Bennetot, B Rabischong, B Aublet-Cuvelier, et al.Journal of Geriatric Psychiatry and Neurology|May 12, 2009
Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performanceHubert H Fernandez, Reiner H See, Matthew F Gary, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|June 20, 2013
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystoniaVirgilio Gerald H Evidente, Hubert H Fernandez, Mark S LeDoux, et al.Parkinsonism & Related Disorders|January 21, 2024
Intrinsic auricular muscle zone stimulation for Parkinson disease: The EARSTIM-PD Phase II multi-center pilot study resultsHubert H Fernandez, Eric A Macklin, Robert A Hauser, et al.Dento Maxillo Facial Radiology|June 24, 2011
Chemical genoprotection: reducing biological damage to as low as reasonably achievable levelsM Alcaraz, D Armero, Y Martínez-Beneyto, et al.Minerva Medica|September 22, 2005
Mood and cognitive changes with deep brain stimulation. What we know and where we should goR L Rodríguez, K Miller, D Bowers, et al.Parkinsonism & Related Disorders|February 15, 2026
Phosphorylated alpha-synuclein skin biopsy alters diagnosis in two out of three patients: Initial findings in a tertiary centerSaar Anis, Avery Kundrick, Camila Callegari Piccinin, et al.Parkinsonism & Related Disorders|August 2, 2023
Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trialHubert H Fernandez, Daniel Weintraub, Eric Macklin, et al.Pageof 65